Japanese scientists have found a new way to treat type I diabetes Type I diabetes mellitus (T1DM) is an autoimmune disease that leads to the irreversible loss of insulin-producing beta cells in the pancreas. University of Tokyo Scientists Develop New Device for Long-Term Transplantation of iPSC-Derived Human Pancreatic Beta Cells.

T1DM develops when autoimmune antibodies destroy the beta cells in the pancreas, which are responsible for insulin production. Insulin regulates blood glucose levels, and in the absence of insulin, high blood glucose levels slowly damage the kidneys, eyes, and peripheral nerves. As the body loses its ability to produce insulin over time, insulin injections are currently the main treatment for type 1 diabetes..

An exciting research challenge over the past decade has been to find ways to replenish lost beta cells through cell therapy..

" “The challenge arises from the difficulty of generating large numbers of human beta cells in a dish and, more importantly, to ensure safe and effective transplantation.. In this study, we wanted to develop a new construct that allows for the successful transplantation of beta cells. in the long term "

To achieve their goal, the researchers developed a lotus root encapsulated construct (LENCON) and packaged it with pancreatic beta cells derived from human iPSCs, which are a limitless source of cells and allow the production of any amount of beta cells..

The need for this method of encapsulation arises from the fact that the recipient's immune cells can destroy recently transplanted cells.. To prevent this from happening, the researchers designed a millimeter-thick LENCON graft.

“These are amazing results that show how LENCON can be used successfully and safely in type 1 diabetes.. Our results indicate that LENCON may offer a new cell therapy option for type I diabetes, ”says first author study Dr. Fumisato Ozawa.

https: // www. medikforum. ru / Keywords:.